Berger Franklin M's Form 4/A amendment
AmendedAtea Pharmaceuticals, Inc.AVIR · filed Jan 17, 2025
- Accession no.
- 0000950170-25-006589
- Filed
- Jan 17, 2025
- Trade date
- Jan 15-16, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Jan 17, 2025
This filing lists 2 non-derivative transactions. Open-market purchases total $81.5K. It was filed 2 days after the trade.
This amendment replaces 0000950170-25-006489 (filed Jan 17, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Berger Franklin MCIK 0001273885 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This Form 4/A has been filed solely to change the code reported in Column 4 of Table I of the Reporting Person's Form 4 filed on January 17, 2025, which had inadvertently noted a "D" instead of "A" to reflect an acquisition of the common stock of Atea Pharmaceuticals, Inc. (the "Company"), due to an administrative error.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.165 to $3.21. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.405. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.